The document discusses survival analysis and Cox regression for cancer clinical trials. It begins with an overview of clinical trials for cancer, noting their complexity, long duration, high costs, and ethical concerns. It then covers survival analysis, describing key concepts like survival curves, hazard functions, and the Kaplan-Meier method for estimating survival when there is censoring. The document provides an example of survival data from a cancer study and discusses assumptions and parameters used in survival analysis like median and mean survival times.
Introduction to survival analysis Providing intuition of hazard function, survival function, cumulative failure function. Life table, KM and log-rank test
In clinical trials and other scientific studies, an interim analysis is an analysis of data that is conducted before data collection has been completed. If a treatment is particularly beneficial or harmful compared to the concurrent placebo group while the study is on-going, the investigators are ethically obliged to assess that difference using the data at hand and to make a deliberate consideration of terminating the study earlier than planned.
In interim analysis, whenever a new drug shows adverse effect on human being while testing the effectiveness of several drugs, we immediately stop the trial by taking into account the fact that maximum number of patients receive most effective treatment at the earliest stage. Interim analysis is also used to possibly reduce the expected number of patients and to shorten the follow-up time needed to make a conclusion. One wouldn't have to spend extra money if he/she already have enough evidence about the outcome. In this presentation, the total sample size is divided into four equal parts to perform the analysis and decision is made based on each individual step.
These annotated slides will help you interpret an OR or RR in clinical terms. Please download these slides and view them in PowerPoint so you can view the annotations describing each slide.
Abstract- Statistical models include issues such as statistical characterization of numerical data, estimating the probabilistic future behaviour of a system based on past behaviour, extrapolation or interpolation of data based on some best-fit, error estimates of observations or model generated output. If the statistical model is used to analyse the survival data it is known as statistical model in survival analysis. There are different statistical data. Censored data is one of its kinds. Censoring means the actual survival time is unknown. Censoring may occur when a person does not experience the event before the study ends or lost to follow-up during the study period or withdraws from the study. For this type of censored data the suitable model is survival models. Survival models are classified as non-parametric, semi-parametric and parametric models. The survival probability can be obtained using these models. Using the health data of cancer registry in Tiruchirappalli, Tamil Nadu , a study on survival pattern of cancer patients was explored, the non-parametric modelling that is Kaplan-Meier method was used to estimate the survival probability and the comparison of survival probability of obtained by life table and Kaplan Meier methods for each stage of the disease were made. Log rank test has been used for the comparison between the estimates obtained at the different stages of the disease.
Introduction to survival analysis Providing intuition of hazard function, survival function, cumulative failure function. Life table, KM and log-rank test
In clinical trials and other scientific studies, an interim analysis is an analysis of data that is conducted before data collection has been completed. If a treatment is particularly beneficial or harmful compared to the concurrent placebo group while the study is on-going, the investigators are ethically obliged to assess that difference using the data at hand and to make a deliberate consideration of terminating the study earlier than planned.
In interim analysis, whenever a new drug shows adverse effect on human being while testing the effectiveness of several drugs, we immediately stop the trial by taking into account the fact that maximum number of patients receive most effective treatment at the earliest stage. Interim analysis is also used to possibly reduce the expected number of patients and to shorten the follow-up time needed to make a conclusion. One wouldn't have to spend extra money if he/she already have enough evidence about the outcome. In this presentation, the total sample size is divided into four equal parts to perform the analysis and decision is made based on each individual step.
These annotated slides will help you interpret an OR or RR in clinical terms. Please download these slides and view them in PowerPoint so you can view the annotations describing each slide.
Abstract- Statistical models include issues such as statistical characterization of numerical data, estimating the probabilistic future behaviour of a system based on past behaviour, extrapolation or interpolation of data based on some best-fit, error estimates of observations or model generated output. If the statistical model is used to analyse the survival data it is known as statistical model in survival analysis. There are different statistical data. Censored data is one of its kinds. Censoring means the actual survival time is unknown. Censoring may occur when a person does not experience the event before the study ends or lost to follow-up during the study period or withdraws from the study. For this type of censored data the suitable model is survival models. Survival models are classified as non-parametric, semi-parametric and parametric models. The survival probability can be obtained using these models. Using the health data of cancer registry in Tiruchirappalli, Tamil Nadu , a study on survival pattern of cancer patients was explored, the non-parametric modelling that is Kaplan-Meier method was used to estimate the survival probability and the comparison of survival probability of obtained by life table and Kaplan Meier methods for each stage of the disease were made. Log rank test has been used for the comparison between the estimates obtained at the different stages of the disease.
Use Proportional Hazards Regression Method To Analyze The Survival of Patient...Waqas Tariq
The Kaplan Meier method is used to analyze data based on the survival time. In this paper used Kaplan Meier procedure and Cox regression with these objectives. The objectives are finding the percentage of survival at any time of interest, comparing the survival time of two studied groups and examining the effect of continuous covariates with the relationship between an event and possible explanatory variables. The variables (Age, Gender, Weight, Drinking, Smoking, District, Employer, Blood Group) are used to study the survival patients with cancer stomach. The data in this study taken from Hiwa/Hospital in Sualamaniyah governorate during the period of (48) months starting from (1/1/2010) to (31/12/2013) .After Appling the Cox model and achieve the hypothesis we estimated the parameters of the model by using (Partial Likelihood) method and then test the variables by using (Wald test) the result show that the variables age and weight are influential at the survival of time.
Logistic Loglogistic With Long Term Survivors For Split Population ModelWaqas Tariq
Split population models are also known as mixture model . The data used in this paper is Stanford Heart Transplant data. Survival times of potential heart transplant recipients from their date of acceptance into the Stanford Heart Transplant program [3]. This set consists of the survival times, in days, uncensored and censored for the 103 patients and with 3 covariates are considered Ages of patients in years, Surgery and Transplant, failure for these individuals is death. Covariate methods have been examined quite extensively in the context of parametric survival models for which the distribution of the survival times depends on the vector of covariates associated with each individual. See [6] for approaches which accommodate censoring and covariates in the ordinary exponential model for survival. Currently, such mixture models with immunes and covariates are in use in many areas such as medicine and criminology. See for examples [4][5][7]. In our formulation, the covariates are incorporated into a split loglogistic model by allowing the proportion of ultimate failures and the rate of failure to depend on the covariates and the unknown parameter vectors via logistic model. Within this setup, we provide simple sufficient conditions for the existence, consistency, and asymptotic normality of a maximum likelihood estimator for the parameters involved. As an application of this theory, the likelihood ratio test for a difference in immune proportions is shown to have an asymptotic chi-square distribution. These results allow immediate practical applications on the covariates and also provide some insight into the assumptions on the covariates and the censoring mechanism that are likely to be needed in practice. Our models and analysis are described in section 5.
El paquete TestSurvRec implementa las pruebas estadíıticas para comparar dos curvas de supervivencia con eventos recurrentes. Este software ofrece herramientas ´utiles para el an´alisis de la supervivencia en el campo de la biomedicina, epidemiolog´ıa, farmac´eutica y otras áreas. El paquete TestSurvRec contiene dos conjuntos de datos con eventos recurrentes, un conjunto de datos referido al experimento de Byar que contiene los tiempos de recurrencia de tumores de c´ancer de vejiga en los pacientes tratados con piridoxina, tiotepa o considerado como un placebo. Y otro conjunto de datos que contiene los tiempos de rehospitalizaci´on despu´es de la cirug´ıa en pacientes con cáncer colorrectal. Estos datos provienen de un estudio que se llev´o a cabo en el Hospital de Bellvitge, un hospital universitario p´ublico en Barcelona (España).
This brief paper will help you to understand survival analysis. This type of analysis is important when the time between exposure and event is of clinical interest. The misconception that mortality and survival are interchangeable comes from the lay use of the terms. Learn more and let me know if you have any questions.
Root cause Analysis (RCA) & Corrective and Preventive action (CAPA) in MRCT d...Bhaswat Chakraborty
This presentation describes Identification & differentiation of Protocol deviation & violation; Different methods of RCA & best suitable method for Multiregional Clinical Trial; CAPA management and CAPA application to other trial sites/CRO/SMO/ Country that is involved in same trial (Strategic Management and application of CAPA in MRCT)
This presentation gives effective solutions to outliers issue in bioequivalence trials. It described what would be acceptable to Regulatory agencies as well as some new approaches.
Equivalence approches for complex generics DIA 11 april 2019 Bhaswat Chakraborty
This is a workshop that i gave a few days ago on bioequivalence of complex generics like peptides, polymers, liposomes, colloids, ophthamic and topical produtcts.
Clinical trials that are needed for efficacy & safety evidence of Medical devices include feasibility (pilot) and Pivotal trials. An extended battery of preclinical trials are also needed for high risk devices.
Writing Science papers for for publication requires something more thatn creativity. Target journals, content organization, wrting style, elegance and referencing are equally important.
Multidisc review of NDAs and BLAs nipicon 2018 Dr. ChakrabortyBhaswat Chakraborty
NDAS and BLAs cannot be authoritatively reviewed these days until experts from different disciplines act together like a team. This presentation give some foundational points and an illustrative example in that regard.
Teaching by stories, anecdotes and historical facts sept 25 2018Bhaswat Chakraborty
Many difficult principles in science and humanities can be taught best by a story (of its discovery), by an anecdote or some historical facts about them.
Orientation and Adaptation for Post-Graduate Pharmacy ProgramsBhaswat Chakraborty
PG Pharmacy programs are more focused and professionally oriented than the undergraduate counterpart. Many soft skills are required along with the curricular competence for excellence at the PG level.
Scientific integrity calls for some basic originality. Plagiarism can destroy this original creativity and ideation. This presentation defines plagiarism (stealing from others' works) and some of the creative and systematic remedies.
Best Practices to Risk Based Data Integrity at Data Integrity Conference, Lon...Bhaswat Chakraborty
Data integrity can be implemented using several approaches. One of the most effective ways to implement DI is a risk based approach. The speaker elaborates this.
There are several dimensions in Pharmaceutical ethics -- Practice-, research- and community oriented. This presentation mainly deals with Clinical research oriented Ethics.
Young pharmaceutical scientists are and can get involved in all aspects of new drug discovery and development. They have to be appropriately qualified, trained and experienced though,
This presentation mainly deals with clinical development of biosimilar products. It also gives enough on non-clinical development so that the audience is well oriented.
High variability in PK can be a characteristic of certain drug products which require different from ordinary strategies and study designs for establishing bioequivalence.
High variability in PK can be a characteristic of certain drug products which require different from ordinary strategies and study designs for establishing bioequivalence.
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
1. Survival Analysis and Cox
Regression for Cancer Trials
Presented at PG Department of Statistics,
Sardar Patel University January 29, 2013
Dr. Bhaswat S. Chakraborty
Sr. VP & Chair, R&D Core Committee
Cadila Pharmaceuticals Ltd., Ahmedabad
1
3. Clinical Trials
Organized scientific efforts to get direct answers from
relevant patients on important scientific questions on
(doses and regimens of) actions of drugs (or devices or
other interventions).
Questions are mainly about differences or null
Modern trials (last 40 years or so) are large, multicentre,
often international and co-operative endeavors
Ideally, primary objectives are consistent with mechanism
of action
Results can be translated to practice
Would stand the regulatory and scientific scrutiny
3
4. Cancer Trials (Phases I–IV)
Highly complex trials involving cytotoxic drugs, moribund patients,
time dependent and censored variables
Require prolonged observation of each patient
Expensive, long term and resource intensive trials
Heterogeneous patients at various stages of the disease
Prognostic factors of non-metastasized and metastasized diseases are
different
Adverse reactions are usually serious and frequently include death
Ethical concerns are numerous and very serious
Trial management is difficult and patient recruitment extremely
challenging
Number of stopped trials (by DSMB or FDA) is very high
Data analysis and interpretation are very difficult by any standard
5
7. India: 2010
7137 of 122 429 study deaths were due to cancer, corresponding to 556 400 national
cancer deaths in India in 2010.
395 400 (71%) cancer deaths occurred in people aged 30—69 years (200 100 men
and 195 300 women).
At 30—69 years, the three most common fatal cancers were oral (including lip and
pharynx, 45 800 [22·9%]), stomach (25 200 [12·6%]), and lung (including trachea
and larynx, 22 900 [11·4%]) in men, and cervical (33 400 [17·1%]), stomach
(27 500 [14·1%]), and breast (19 900 [10·2%]) in women.
Tobacco-related cancers represented 42·0% (84 000) of male and 18·3% (35 700) of
female cancer deaths and there were twice as many deaths from oral cancers as lung
cancers.
Age-standardized cancer mortality rates per 100 000 were similar in rural (men 95·6
[99% CI 89·6—101·7] and women 96·6 [90·7—102·6]) and urban areas (men 102·4
[92·7—112·1] and women 91·2 [81·9—100·5]), but varied greatly between the
states.
Cervical cancer was far less common in Muslim than in Hindu women (study deaths
24, age-standardized mortality ratio 0·68 [0·64—0·71] vs 340, 1·06 [1·05—1·08]).
8
9. Survival Analysis
Survival analysis is studying the time between entry
to a study and a subsequent event (such as death).
Also called “time to event analysis”
Survival analysis attempts to answer questions such
as:
which fraction of a population will survive past a certain
time ?
at what rate will they fail ?
at what rate will they present the event ?
How do particular factors benefit or affect the probability of
survival ?
11
10. What kind of time to event data?
Survival Analysis typically focuses on time to event data.
In the most general sense, it consists of techniques for
positive-valued random variables, such as
time to death
time to onset (or relapse) of a disease
length of stay in a hospital
money paid by health insurance
viral load measurements
Kinds of survival studies include:
clinical trials
prospective cohort studies
retrospective cohort studies
retrospective correlative studies
12
11. Definition and Characteristics of Variables
Survival time (t) random variables (RVs) are always non-
negative, i.e., t ≥ 0.
T can either be discrete (taking a finite set of values, e.g.
a1, a2, …, an) or continuous [defined on (0,∞)].
A random variable t is called a censored survival time RV
if x = min(t, u), where u is a non-negative censoring
variable.
For a survival time RV, we need:
(1) an unambiguous time origin (e.g. randomization to clinical
trial)
(2) a time scale (e.g. real time (days, months, years)
(3) defnition of the event (e.g. death, relapse)
13
12. Event
Test
Non-Event
Sample of Target Randomize
Population
Event
Control
Non-Event
Time to Event
14
14. Characterization of Survival
There are several equivalent ways to characterize the
probability distribution of a survival random variable.
We will use the following terms:
The density function f(t)
The survival or survivor function S(t)
The hazard function H(t)
The cumulative hazard function Λ(t)
Median survival, called τ, is defined as
S(τ ) = 0.5
Similarly, any other percentiles could be defined
Practically, we estimate median survival as the smallest
time τ such that
Ŝ (τ) ≤ 0.5
16
15. Estimation of Survival Function from
Censored Data
Hazard shapes can be increasing (e.g. aging after 65),
decreasing (e.g. survival after surgery), bathtub (e.g. age-
specifc mortality) or constant (e.g. survival of patients with
advanced chronic disease)
If there are censored observations, then Ŝ(t) by a parametric
method is not a good estimate of the true S(t), so non-
parametric methods must be used to account for censoring
(life-table methods, Kaplan-Meier estimator)
Kaplan-Meier estimator is the most popular
However, theoretically (or when conditions are met) survival
data can be fit to parametric models as well
17
17. Survival Rate by Kaplan Meier
This function estimates survival rates and hazard from data that may be incomplete.
The survival rate is expressed as the survivor function (S):
where t is the survival time
e.g. 2 years in the context of 5 year survival rates
Sometimes S is estimated as the probability of surviving to time t for those alive just
before t multiplied by the proportion of subjects surviving to t
Calculated by product limit (PL) method 1 or the simpler Nelson-Aalen estimate2,
estimate of which is always less than a Peterson estimate
Peterson PL Method Nelson-Aalen Method
where ti is duration of study at point i, di is number of deaths up to point i and ni is
number of individuals at risk just prior to ti.
19
18. Data
Following example is data of death from a cancer after
exposure to a particular carcinogen in two groups of patients.
Group 1 had a different pre-treatment régime to group 2
The time from pre-treatment to death is recorded.
If a patient was still living at the end of the experiment or it
had died from a different cause then that time is considered
censored (* below). A censored observation is given the value
0 in the death/censorship variable to indicate a "non-event".
Group 1: 143, 165, 188, 188, 190, 192, 206, 208, 212, 216, 220, 227, 230,
235, 246, 265, 303, 216*, 244*
Group 2: 142, 157, 163, 198, 205, 232, 232, 232, 233, 233, 233, 233, 239,
240, 261, 280, 280, 295, 295, 323, 204*, 344*
20
19. Assumptions
S is based upon the probability that an individual survives at
the end of a time interval, on the condition that the individual
was present at the start of the time interval. S is the product (P)
of these conditional probabilities.
If a subject is last followed up at time ti and then leaves the study for any reason
(e.g. lost to follow up) ti is counted as their censorship time.
Censored individuals have the same prospect of survival as
those who continue to be followed. This can not be tested for
and can lead to a bias that artificially reduces S.
Survival prospects are the same for early as for late recruits to
the study (can be tested for).
The event studied (e.g. death) happens at the specified time.
Late recording of the event studied will cause artificial
inflation of S.
21
20. Other Parameters
The cumulative hazard function (H) is the risk of event 2 (e.g. death) at time t
S and H with their standard errors and confidence intervals need to be saved
Median and mean survival time
The median survival time is calculated as the smallest survival time for which the survivor
function is less than or equal to 0.5.
Some data sets may not get this far, in which case their median survival time is not
calculated.
A confidence interval for the median survival time can be constructed using a robust non-
parametric method or using a large sample estimate of the density function of the survival
estimate
Mean survival time is estimated as the area under the survival curve. The estimator is based
upon the entire range of data
Some software uses only the data up to the last observed event; this biases the estimate of
the mean downwards, entire range of data should be used
Samples of survival times are frequently highly skewed, therefore, in survival analysis, the
median is generally a better measure of central location than the mean
22
21. Variances of S & H hat
The variance of S
The confidence interval for the survivor function is not calculated directly using
Greenwood's variance estimate as this would give impossible results (< 0 or > 1) at
extremes of S. The confidence interval for S uses an asymptotic maximum likelihood
solution by log transformation
The variance of H hat is estimated as:
23
22. Cancer Trial Data Preparation
Data is very complex, statistical skills & insight are necessary
Time-to-event:
time a patient in a trial survived
time to tumor progression or relapse in a patient
Event / censor code: 1 or 0
1 for event(s) happened
0 for no event or lost to follow up but survival assumed
Stratification:
e.g. centre code for a multi-centre trial
Be careful with your choice of strata
Predictors (covariates):
which can be a number of variables that are thought to be related to the
event under study, e.g., drug treatment, disease stage
24
25. Descriptive Stats Group 1
Median survival time = 216
Andersen 95% CI for median survival time = 199.62 to
232.382
Brookmeyer-Crowley 95% CI for median survival time = 192
to 230
Mean survival time (95% CI) = 218.68 (200.36 to 237.00)
27
27. Descriptive Stats Group 2
Median survival time = 233
Andersen 95% CI for median survival time = 231.89 to 234.10
Brookmeyer-Crowley 95% CI for median survival time = 232
to 240
Mean survival time (95% CI) = 241.28 (219.59 to 262.98)
29
32. Comparing Survival Functions
Due to the censoring, classical tests such as t-test and
Wilcoxon test cannot be used for the comparison of the
survival times
Various tests have been designed for the comparison of
survival curves, when censoring is present
• The most popular ones are:
Logrank (or Cox-Mantel or Mantel-Haenszel) test
Wilcoxon (Gehan) test
The Logrank test has more power than Wilcoxon for detecting
late differences
The Logrank test has less power than Wilcoxon for detecting
early differences
The logrank statistic is distributed as χ2 with a H0 that survival
functions of the two groups are the same
34
34. Cox-Mantel Log Rank Test
Group Events observed Events expected
1 17 12.20368414
2 20 24.79631586
Degrees of
Chi-square Freedom P
3.124689787 1 0.077114564
The test statistic for equality of survival across the k groups
(populations sampled) is approximately chi-square distributed
on k-1 degrees of freedom.
36. Case Study
• Purpose: This, the largest randomized study in pancreatic
cancer performed to date, compares marimastat, the first of
a new class of agents, with gemcitabine
• Context: The prognosis for unresectable pancreatic cancer
remains dismal (1-year survival rate, < 10%; 5-year
survival rate, < 5%)
– Recent advances in conventional chemotherapy and novel
molecular treatment strategies warrant investigation
38
37. Case Study: Patients
• Histologically or cytologically proven adenocarcinomas of the pancreas
– unresectable on computed tomographic imaging
• Tumors were staged
– Using the International Union Against Cancer tumor-node-metastasis classification
– Stage-grouped according to the American Joint Committee on Cancer Staging criteria for
pancreatic cancer
• Inclusion Criteria
– Patients entered the study within 8 wks of initial diagnosis or within 8 weeks of recurrence after
prior surgery
– >18 years
– Karnofsky performance status (KPS) of at least 50%
– At entry, patients had to have adequate bone marrow reserves, defined 1,000/µL of
granulocytes, platelet 100,000/µL, and Hb 9 g/dL.
– Adequate baseline hepatic function (bilirubin 2 x ULN; AST, ALT, or alkaline phosphatase 5 x
ULN)
– Adequate renal function (creatinine 2 x ULN)
• Exclusion Criteria
– Any fprevious systemic anticancer therapy as a primary intervention for locally advanced or
metastatic disease
– Prior exposure to a metalloproteinase inhibitor or gemcitabine
– Patients with prior adjuvant or consolidation chemotherapy or radiotherapy and relapsed within
6 months after therapy
– Pregnant or lactating patients were excluded
– Patients who had other investigational agents within 4 weeks before study start
39
38. Case Study: End Points
• The primary study end point
– Overall survival, along with prospectively defined comparisons
between gemcitabine and marimastat 25 mg bid and between
gemcitabine and marimastat 10 mg bid
– Secondary study end points
• Progression-free survival
• Patient benefit s
– quality of life [QOL], weight loss, pain, analgesic consumption, surgical
intervention to alleviate cancer symptoms, and KPS)
• Safety and tolerability
• Tumor response rate was also assessed
40
39. Case Study: Randomization & Treatments
Randomization
IC obtained from each patient before study entry
A computer-generated random code used according to the method of minimization. This
method balanced the treatment groups on the basis of stage of disease (stage I/II, III, or IV),
KPS (50% to 70% v 80% to 100%), sex, disease status (recurrent v newly diagnosed), and
study center.
Patients received
either 5 mg, 10 mg, or 25 mg of marimastat bid orally
or 1,000 mg/m2 of gemcitabine hydrochloride by intravenous infusion
The marimastat dosage was double-blinded but allocations to marimastat or gemcitabine
were open-label due to the different modes of administration
Treatment
Marimastat: 5 mg bid, 10 mg bid, or 25 mg bid with food. The dose of marimastat could be
reduced if musculoskeletal or other toxicities developed.
Gemcitabine: 1,000 mg/m2 weekly for the first 7 weeks, no treatment in week 8, 1,000 mg/m2
weekly for 3 weeks next and nothing in the fourth week. Dose reduction (25%) permitted at
granulocyte 0.5-0.99/µL or platelet 50,000 to 99,999/µL
If the counts were lower after the lower dose, the next dose was omitted.
Patients who could not be treated for 6 weeks as a result of toxicity were withdrawn from the
study. No concomitant anticancer therapy
41
40. Case Study: Statistical Analysis
Sample size (n= 400: 100 per group); based on absolute
differences in survival rates at 18 months of 14.5%, power of
80% and using a significance level of .025 (log-rank test,
Bonferoni adjusted)
• Also based on 10% survival rate at study censure with gemcitabine and a
mortality rate 75.5% in 10- or 25-mg marimastat groups
Data Analysis
• Intent-to-treat -- Kaplan-Meier
• Cox proportional hazards model to identify prognostic factors and to explore their
influence on the comparative hazard of death between the treatment groups
• Plots of Log (-Log, survivor function) versus time for each individual variable
were produced to ensure proportional hazard assumptions were met
• In all survival analyses, patients who were lost to follow-up were censored at
their last known date alive.
• Proportions were tested using the χ2 test. Patient benefit data were tested using the
Wilcoxon rank sum test, and repeated measures analysis was applied to the QOL
data.
42
42. Primary mortality analysis by treatment arm
log-rank test,
P = .0001
Bramhall, S. R. et al. J Clin Oncol; 19:3447-3455 2001
44
43. Case Study: Results
The 1-year survival rate:
was 19% for the gemcitabine group and 20% for the marimastat 25-mg group (χ2
test, P = .86). The 1-year survival rate for both the 10-mg and 5-mg groups was
14%
Progression-free survival:
revealed a significant difference between the gemcitabine group and each of the
three marimastat treatment groups (log-rank test, P = .0001), with median
progression-free survivals of 115, 57, 59, and 56 days for gemcitabine,
marimastat 25-, 10-, and 5-mg groups, respectively
Cox proportional hazards:
Factors associated with increased mortality risk were male sex, poor KPS (< 80),
presence of liver metastases, high serum lactate dehydrogenase, and low serum
albumin.
Adjusted for these variables, there was no statistically significant difference in
survival rates between patients treated with gemcitabine and marimastat 25 mg,
but patients receiving either marimastat 10 or 5 mg were found to have a
significantly worse survival rate than those receiving gemcitabine
45
48. References
1. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations.
Journal of the American Statistical Association (1958); 53: 457-481
2. Peterson AV Jr.. Expressing the Kaplan-Meier estimator as a function of
empirical subsurvival functions. Journal of the American Statistical Association
(1977); 72: 854-858
3. Nelson W. Theory and applications of hazard plotting for censored failure data.
Technometrics (1972); 14: 945-966
4. Aalen OO. Non parametric inference for a family of counting processes. Annals
of Statistics 1978; 6: 701-726.
5. R. Peto et al. Design and analysis of randomized clinical trials requiring
prolonged observation of each patient. British Journal of Cancer (1977); 31: 1-
39.
50